• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

健康受试者中替加环素耐受性的暴露-反应分析。

Exposure-response analyses of tigecycline tolerability in healthy subjects.

作者信息

Passarell Julie, Ludwig Elizabeth, Liolios Kathryn, Meagher Alison K, Grasela Thaddeus H, Babinchak Timothy, Ellis-Grosse Evelyn J

机构信息

Pharmacologic Division, Cognigen Corporation, Buffalo, NY 14221, USA.

出版信息

Diagn Microbiol Infect Dis. 2009 Oct;65(2):123-9. doi: 10.1016/j.diagmicrobio.2009.06.019.

DOI:10.1016/j.diagmicrobio.2009.06.019
PMID:19748422
Abstract

Tigecycline exposure (area under the concentration-time curve [AUC((0-infinity))] and maximum serum concentration [C(max)]) and first occurrence of nausea and vomiting were evaluated in 136 healthy subjects after 12.5- to 300-mg single doses. Nausea was more frequent in females (46%, 10/22) compared with males (31%, 11/36) after 100-mg doses. Most nausea (vomiting) events occurred < or =4 h (<6 h) after tigecycline. For doses < or =100 mg, the median duration of nausea and vomiting was approximately 5 h. Based on logistic regression, increased exposure (AUC((0-infinity)) >C(max)) to tigecycline results in an increased rate of nausea (P < or = .0001; = .0022) and vomiting (P < or = .0001; = .0006). At the median AUC((0-infinity)) (C(max)) for the 50-mg dose group, the probability of nausea and vomiting was 0.26 (0.29) and 0.07 (0.11), respectively. Model-predicted rates of nausea and vomiting were comparable with those observed for the tetracycline class of antibiotics, with tolerable rates predicted after 50-mg doses of tigecycline.

摘要

在136名健康受试者单次服用12.5至300毫克替加环素后,评估了替加环素暴露量(浓度-时间曲线下面积[AUC((0-无穷大))]和血清最大浓度[C(max)])以及恶心和呕吐首次出现的情况。服用100毫克剂量后,女性恶心的发生率(46%,10/22)高于男性(31%,11/36)。大多数恶心(呕吐)事件发生在替加环素给药后≤4小时(<6小时)。对于≤100毫克的剂量,恶心和呕吐的中位持续时间约为5小时。基于逻辑回归分析,替加环素暴露量增加(AUC((0-无穷大))>C(max))会导致恶心发生率增加(P≤.0001;=.0022)和呕吐发生率增加(P≤.0001;=.0006)。在50毫克剂量组的中位AUC((0-无穷大))(C(max))时,恶心和呕吐的概率分别为0.26(0.29)和0.07(0.11)。模型预测的恶心和呕吐发生率与四环素类抗生素观察到的发生率相当,50毫克剂量的替加环素预测的发生率可耐受。

相似文献

1
Exposure-response analyses of tigecycline tolerability in healthy subjects.健康受试者中替加环素耐受性的暴露-反应分析。
Diagn Microbiol Infect Dis. 2009 Oct;65(2):123-9. doi: 10.1016/j.diagmicrobio.2009.06.019.
2
Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects.健康受试者单次及多次给药后替加环素的药代动力学
Antimicrob Agents Chemother. 2005 Jan;49(1):220-9. doi: 10.1128/AAC.49.1.220-229.2005.
3
Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline.替加环素的稳态血清及肺内药代动力学与药效学
Int J Antimicrob Agents. 2005 Jun;25(6):523-9. doi: 10.1016/j.ijantimicag.2005.02.013.
4
Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects.一流的甘氨酰环素类抗生素[14C]替加环素静脉输注健康男性受试者后的代谢、排泄及药代动力学
Drug Metab Dispos. 2007 Sep;35(9):1543-53. doi: 10.1124/dmd.107.015735. Epub 2007 May 30.
5
Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose.单次100毫克剂量后替加环素的血清、组织和体液浓度。
J Antimicrob Chemother. 2006 Dec;58(6):1221-9. doi: 10.1093/jac/dkl403. Epub 2006 Sep 29.
6
Pharmacokinetics and safety of a single intravenous dose of the antibiotic tigecycline in patients with cirrhosis.肝硬化患者单次静脉注射抗生素替加环素的药代动力学和安全性。
J Clin Pharmacol. 2011 Jan;51(1):93-101. doi: 10.1177/0091270010363477. Epub 2010 Mar 22.
7
Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin.静脉注射替加环素治疗社区获得性肺炎的安全性和有效性:与左氧氟沙星的双盲随机3期对照研究结果
Diagn Microbiol Infect Dis. 2009 Jan;63(1):52-61. doi: 10.1016/j.diagmicrobio.2008.09.001. Epub 2008 Nov 5.
8
Evaluation of a potential tigecycline-warfarin drug interaction.替加环素与华法林潜在药物相互作用的评估。
Pharmacotherapy. 2008 Jul;28(7):895-905. doi: 10.1592/phco.28.7.895.
9
Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model.替加环素对鲍曼不动杆菌所致小鼠肺炎模型的药效学评价
J Antimicrob Chemother. 2009 May;63(5):982-7. doi: 10.1093/jac/dkp056. Epub 2009 Mar 11.
10
Population pharmacokinetics of tigecycline in healthy volunteers.替加环素在健康志愿者中的群体药代动力学。
J Clin Pharmacol. 2007 Jun;47(6):727-37. doi: 10.1177/0091270007300263.

引用本文的文献

1
Calculated initial parenteral treatment of bacterial infections: Safety and tolerabilty.细菌性感染的初始肠外治疗方案计算:安全性与耐受性
GMS Infect Dis. 2020 Mar 26;8:Doc16. doi: 10.3205/id000060. eCollection 2020.
2
Comparison of Tigecycline or Cefoperazone/Sulbactam therapy for bloodstream infection due to Carbapenem-resistant .比较替加环素或头孢哌酮/舒巴坦治疗碳青霉烯类耐药. 引起的血流感染。
Antimicrob Resist Infect Control. 2019 Mar 6;8:52. doi: 10.1186/s13756-019-0502-x. eCollection 2019.
3
Randomized, Double-Blind, Placebo-Controlled Studies of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Eravacycline.
随机、双盲、安慰剂对照研究依拉环素单剂量和多剂量递增的安全性和药代动力学。
Antimicrob Agents Chemother. 2018 Oct 24;62(11). doi: 10.1128/AAC.01174-18. Print 2018 Nov.
4
Tigecycline does not prolong corrected QT intervals in healthy subjects.替加环素不会延长健康受试者的校正 QT 间期。
Antimicrob Agents Chemother. 2013 Apr;57(4):1895-901. doi: 10.1128/AAC.01576-12. Epub 2013 Feb 12.
5
Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease.系统评价和荟萃分析替加环素治疗感染性疾病的有效性和安全性。
Antimicrob Agents Chemother. 2011 Mar;55(3):1162-72. doi: 10.1128/AAC.01402-10. Epub 2010 Dec 20.